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Abstract
Background: Skin and soft tissue infections (SSTIs) are a leading cause of morbidity and mortality among people
who inject drugs (PWID). International data indicate up to one third of PWID have experienced an SSTI within the
past month. Complications include sepsis, endocarditis and amyloid A (AA) amyloidosis. AA amyloidosis is a serious
sequela of chronic SSTI among PWID. Though there is a paucity of literature reporting on AA amyloidosis among
PWID, what has been published suggests there is likely a causal relationship between AA amyloidosis and injecting-
related SSTI. If left untreated, AA amyloidosis can lead to renal failure; premature mortality among diagnosed PWID
is high. Early intervention may reverse disease. Despite the high societal and individual burden of SSTI among
PWID, empirical evidence on the barriers and facilitators to injecting-related SSTI prevention and care or the
feasibility and acceptability of AA amyloidosis screening and treatment referral are limited. This study aims to fill
these gaps and assess the prevalence of AA amyloidosis among PWID.
Methods: Care and Prevent is a UK National Institute for Health Research-funded mixed-methods study. In five
phases (P1–P5), we aim to assess the evidence for AA amyloidosis among PWID (P1); assess the feasibility of AA
amyloidosis screening, diagnostic and treatment referral among PWID in London (P2); investigate the barriers and
facilitators to AA amyloidosis care (P3); explore SSTI protection and risk (P4); and co-create harm reduction
resources with the affected community (P5). This paper describes the conceptual framework, methodological
design and proposed analysis for the mixed-methods multi-phase study.
Results: We are implementing the Care and Prevent protocol in London. The systematic review component of the
study has been completed and published. Care and Prevent will generate an estimate of AA amyloidosis prevalence
among community recruited PWID in London, with implications for the development of screening recommendations
and intervention implementation. We aim to recruit 400 PWID from drug treatment services in London, UK.
Conclusions: Care and Prevent is the first study to assess screening feasibility and the prevalence of positive
proteinuria, as a marker for AA amyloidosis, among PWID accessing drug treatment services. AA amyloidosis is a
serious, yet under-recognised condition for which early intervention is available but not employed.
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Background
Skin and soft tissue infections (SSTIs) are a preventable
cause of morbidity and mortality among people who inject
drugs (PWID) [1, 2]. Timely health care access for
injecting-related SSTIs is suboptimal, indicating a dearth of
acceptable interventions [3, 4]. A recent systematic review
evidences wide variation in lifetime prevalence (6–69%)
with up to a third of PWID reporting SSTIs within the past
month [5]. SSTI-related complications are a leading cause
of hospitalisation among PWID [4, 6–10], with hospital ad-
mission rates doubling in the USA between 1993 and 2010
[4] and increasing annually in the UK since 2012 [10]. In
the UK, 36% of PWID report a recent symptom of a bac-
terial infection [11], with 10% admitted to hospital with
SSTI complications annually [7]. Most of these hospitalisa-
tions are avoidable and are often due to delays in primary
care access [7, 12, 13]. Recurrence of SSTIs among PWID
is common and associated with repeat hospital visits, poor
antibiotic adherence, surgical intervention, hospital dis-
charge against medical advice and social factors such as
homelessness [14, 15]. Complications associated with
delayed SSTI care include sepsis, gangrene, endocarditis,
chronic venous ulcers and amyloid A (AA) amyloidosis—
potentiating surgical debridement, limb amputation, renal
failure and death [6, 13, 16–19]. Economic implications
are substantive; costs to the US health care system were
approximately US$193 million in 2001 and costs to the
UK health care system were assessed to be approxi-
mately £77 million per annum between July 2005 and
July 2009 in 2012 [8].
Injecting-related SSTIs are a ‘hidden epidemic of suffer-
ing’ [20]. They impact the most marginalised: those who
are homeless or unstably housed and those who are often
economically insecure and living with multiple morbidities
[21]. Women who inject drugs are often disproportion-
ately affected [5, 11, 21]. SSTI complications are exacer-
bated by and can entrench experiences of social exclusion
[22]. The stigma, shame, pain, unpleasant odour and
mobility restrictions associated with complications, such
as chronic leg ulcers, can restrict social integration, access
to care and reduction of illicit drug use [3, 19, 21, 22].
Knowledge among PWID about SSTI care and complica-
tions is reportedly poor [23, 24], with practices such as
lancing abscesses, inappropriate antibiotic use and poor
antibiotic adherence potentially increasing wound severity,
duration and recurrence [22, 25–27].
A research and policy focus on blood-borne viruses
among PWID has foreclosed attention to this concern.
Hepatitis C and HIV prevention is a primary remit of
harm reduction services [28]. Resource constraints, due to
political pressures and austerity measures in the countries
such as the US and the UK, further hamper the ability of
services to offer SSTI care and advice [29, 30]. Contextual
information to inform interventions is crucial, given the
geographical variation in injecting patterns, drug forms,
service availability and associated SSTI risk [4, 31]. Pub-
lished research on SSTI among PWID in the UK is pri-
marily epidemiological, demonstrating population and
health care burden [7, 12, 13, 21, 32, 33], but providing lit-
tle insight into reasons for delayed care access. The scant
UK qualitative literature addressing injecting-related SSTI
focuses on venous ulcers [22, 34]. To date, no published
studies have focused on the barriers and facilitators to
timely SSTI care access among PWID in the UK.
SSTI-related complications such as AA amyloidosis
are also poorly understood. AA amyloidosis results from
persistent inflammation, a feature of untreated SSTIs.
Evidence indicates that it has become the predominant
cause of progressive renal disease among PWID [35]. If
not effectively treated, AA amyloidosis can lead to renal
failure, necessitating dialysis or kidney transplantation
[36]. PWID experience considerable difficulties adhering
to dialysis treatment, with a median survival time from
diagnosis of 19 months in the UK [16]. This is a poten-
tially preventable condition; early risk screening, regular
wound care and injecting cessation can prevent and re-
verse disease progression [16]. Prevalence of AA amyl-
oidosis among PWID is unknown, and no UK drug
treatment services are known to currently provide rou-
tine AA amyloidosis risk screening or early intervention.
The limited extant literature indicates that there is an
urgent need for research to investigate the barriers and fa-
cilitators to expedient SSTI care among PWID, including
the feasibility of AA screening in drug treatment settings
and referral to specialty care, to inform effective and ac-
ceptable SSTI care interventions. This paper describes the
conceptual framework, methodological design and pro-
posed analysis for the mixed-methods multi-phase study.
Care and Prevent will generate an estimate of SSTI bur-
den and AA amyloidosis prevalence among PWID using
drug treatment services in London, with implications for
the development of screening recommendations and SSTI
interventions among PWID.
Conceptual framework
Counterpublics and care
We draw on two orientating concepts: ‘counterpublic
health’, attentive to the role of corporeal learning in
sustaining collective change among marginalised popula-
tions [37], and an ‘ethic of care’, attentive to the situated
rationalities informing care practices [38]. A ‘counter-
public health’ ethos recognises that public health goals,
and the notions of health inscribed within them, do not
speak to all ‘publics’. This recognition is both political
and pragmatic: it works to identify and enhance the
processes through which people look after themselves
and, by drawing on embodied practice, promote the dif-
fusion of collective change. Sex- and pleasure-positive
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HIV/AIDS interventions informed by gay community
practice provide an example [37]. An ethic of care is
attuned to specificities of practice in context: the envi-
ronments, relationships and rationalities informing risk
and protective practice. In this way, study aims are both
applied and theoretical: to enable the practical develop-
ment of health care interventions for PWID and to
advance sociological theories of care and counterpublics.
Commensurate with both aims is a focus on practice,
with analysis attuned to the social practices and rela-
tional networks within which care is embedded as
well as the alternative rationalities that can inform
these practices.
Participatory research
A participatory research paradigm informs the study.
This can be characterised by two core elements: ‘the
specific quality of interaction between those conducting
research and those whose lives are the focus of the re-
search’ and ‘an inherent and often explicit connection
between research and social action, the former designed
to support the latter’ ([39], p. 117). Our participatory
approach seeks to enable participants’ ownership and
co-production of the research process [40] rather than
just facilitate consultative forms of ‘involvement’ in re-
search. Members of the affected community are active in
the initiation, design and process of the study and will
work with the research team to translate findings into
meaningful and transformative practice. The principal
investigator, coming from a PWID background [41], has
an established track record of working with marginalised
communities in the design, implementation and out-
comes of research.
Positive deviance
Our focus on care and protection, as well as risk, is
informed by a positive deviance methodology as operatio-
nalised in previous research by the study PI [42–46]. Most
research investigating injecting-related harms focuses on
‘incident’ cases. In ‘positive deviance’ designs, the ap-
proach is the reverse, that is, to explore accounts of pro-
tection in contexts of high risk in order to learn about the
practices shaping avoidance of infection and resilience to
risk. In phase 4 of the study, we will purposively sample
PWID who have comparable injecting histories but differ-
ing experience (extensive vs none/limited) of SSTIs. A
dual focus on protection and risk enables investigation
into successful SSTI self-care practices among PWID: cru-
cial for informing the development of community accept-
able and effective interventions. We are interested in how
injecting-related wound care is cultivated and sustained in
contexts of social and economic marginalisation and the
conditions under which this care is constrained or be-
comes undone. Life history interviews and timelines will
be employed and co-constructed to enable exploration of
the interrelationships informing SSTI prevention, occur-
rence and chronicity over time. These methods, by
broadening enquiry beyond the injecting history, also
allow exploration of indirect social conditional factors
not proximal to risk [42–45].
Methods
Care and Prevent (‘Promoting skin and soft tissue infec-
tion care and preventing AA amyloidosis renal failure
among people who inject drugs in the United Kingdom:
a mixed-methods multi-phase study’) is a UK National
Institute of Health Research (NIHR)-funded study seek-
ing to improve SSTI prevention, care and treatment
interventions for PWID. This includes assessing the
feasibility of screening, diagnosis and treatment referral
for AA amyloidosis in UK drug treatment services.
Approach
This multi-phase study employs mixed methods to ad-
dress six primary objectives. We aim to (1) assess the
evidence for AA amyloidosis among PWID; (2) test
the feasibility of screening for AA amyloidosis in drug
treatment services; (3) estimate the prevalence of SSTI
and AA amyloidosis among PWID in London; (4)
identify barriers and facilitators to the AA amyloidosis
care pathway; (5) understand the factors informing
SSTI risk, protection and care among PWID; and (6)
develop SSTI and AA amyloidosis harm reduction
resources in collaboration with PWID and service pro-
viders. These objectives are operationalised across the
five phases. Phases 1 (assessing the evidence) and 2
(survey and screening) run concurrently. These are
followed by two qualitative phases, also running con-
currently: 3 (the AA amyloidosis pathway) and 4 (SSTI
risk and care). Phase 5, incorporating collaborative
resource development workshops, finalises the study,
drawing on analyses and findings from the previous
phases (see Fig. 1).
Fig. 1 Multi-phase design
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Study phases, sites and recruitment
Phase 1: assessing the evidence
We will conduct a systematic review on AA amyloidosis
among PWID. The details of the methods and findings
of systematic review will be published elsewhere [47].
Phase 2: survey development
We developed an 83-item computer-assisted question-
naire, through an iterative process involving the research
team, project meetings and comparisons with extant
surveys, e.g. the UK unlinked anonymous survey, with
the objective of assessing the prevalence of key measures
and identifying modifiable behavioural risks, and risk
factors, for both SSTI and AA amyloidosis among PWID
participants (see Additional file 1). Question domains
cover injecting and substitution treatment history; drug
preparation and hygiene practices; injecting frequency
and administration sites; SSTI symptoms and diagnosis;
SSTI health care access and hospitalisations; other diag-
nosed health conditions; demographics, including home-
lessness history; and screening outcome, referral and
consent for follow-up contact. Of note are detailed ques-
tions regarding acidifier use (type, duration and amount)
for drug injection preparation, given characteristics of
the brown heroin (base) predominant in the UK, and the
authors (MH and DC) published hypothesis that overly
acidic drug solution contributes to venous damage and
SSTI risk among this population [48].
The questionnaire has been uploaded onto hand-held
tablets using Open Data Kit (ODK) software. Question-
naires were pilot-tested with a small sample of PWID
(n = 5) to check for problems with interpretation of
questions, question flow, sensitive/problematic ques-
tions and completion time, and suggestions for im-
provement were incorporated into the final instrument.
Questionnaires are researcher-administered (MH or
RB), to aid consistency and reduce participant burden—
particularly given the variable literacy of the study
population. We have incorporated photographs of cel-
lulitis, abscesses and venous disease for participants to
refer to when indicating type and severity of current
and previous SSTIs. We will take close-up, anonymous,
photographs of participants’ current SSTIs with their
consent. These will be uploaded into the participant’s
anonymised questionnaire file, enabling comparison
with participant self-identified SSTI attribution and
severity. On completion, questionnaire data are trans-
ferred to the secure London School of Hygiene & Trop-
ical Medicine (LSHTM) ODK server, protecting against
loss or theft of mobile device.
Screening and referral
Alongside the questionnaire, participants will be asked to
provide a urine sample, to be screen tested for proteinuria,
using an albumin to creatinine ratio measure. Point-of-
care testing is conducted using a portable CLINITEX
Status Analyzer machine and Microalbumin Reagent
Strips. Where possible, all samples with an abnormal read-
ing are sent for laboratory testing verification through the
respective recruiting services. Participants receive CLINI-
TEX testing results immediately; those with an albumin to
creatinine ratio of > 30 mg/mmol receive a referral to the
National Amyloidosis Centre (NAC) for specialist assess-
ment. Peer support for NAC appointment attendance is
provided through Groundswell, a homeless peer advocacy
service (http://groundswell.org.uk/). Trained Groundswell
peer advocates will contact participants prior to their first
appointment, assess their needs regarding attendance,
accompany them to and from the day-long appointment
and provide support for duration.
The NAC assessment process is standard UK National
Health Service (NHS) care [49]. Clients will be asked to
consent to their assessment outcome details being
shared with the research team, but no additional tests or
procedures will be carried out for the study. NAC diag-
nostic practice involves an SAP scintigraphy (99% speci-
ficity and sensitivity for AA amyloidosis). Participants
with amyloid deposition on SAP scintigraphy will be
diagnosed with AA amyloidosis and receive monitoring.
Those with evidence of high amyloid burden and/or ad-
vanced kidney disease will be referred for dialysis treat-
ment. Those with low or moderate amyloidosis burden
will be closely monitored and advised by NAC providers
to cease injecting (supported by opiate substitution ther-
apy referral) and resolve any current SSTIs in order to
prevent disease progression. Monthly blood measure-
ments of serum amyloid A protein (SAA) will ascertain
disease progression or stabilisation. Diagnostic and treat-
ment uptake data for each case will be collected by NAC
providers and made available for analysis, with partici-
pants’ consent. Participants with positive proteinuria
screen but no amyloid will be referred to a non-NAC
kidney specialist.
Sample size, eligibility criteria and recruitment strategy
for phase 2
We aim to recruit 400 PWID for phase 2. The sample size
has been calculated based on feasibility (numbers attend-
ing the clinics and likely response rate) and on an esti-
mated low prevalence outcome (5% +proteinuria) but
common risk factor (untreated SSTI). The sample size will
be sufficient to estimate prevalence of +proteinuria ± 2%
and, allowing for some attrition, to follow through the
diagnostic and treatment pathway (~ 15 participants).
Phase 2 eligibility criteria are psychoactive drug injection
history, client of the recruiting service, aged 18 and over,
capable of providing informed consent and English lan-
guage proficiency. Broad eligibility criteria (ever injecting,
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rather than current injecting or SSTI history) protect
against bias: enabling generalisable prevalence estimates of
SSTIs and AA amyloidosis risk. Recruitment sites are drug
treatment services located in Central, North, South and
West London. London has been chosen due to high preva-
lence of PWID, and varied service locations enables access
to diverse PWID communities. Recruitment is facilitated
through flyers on service waiting room walls and provided
by service staff to eligible clients. Participants are pro-
vided with a £10 supermarket voucher for their time.
Members of the research team attend each site for pre-
determined periods each week and made themselves
available to answer client questions, assess eligibility
and conduct data generation.
Phase 3: the AA amyloidosis pathway
We will qualitatively explore experiences of the AA amyl-
oidosis care pathway. Phase 3 participants will be sampled
from recruitment site clients previously diagnosed with
AA amyloidosis (n = 5–10) and those referred to the
NAC, from phase 2, who consent to qualitative follow-up
(n = ~ 10). Previously diagnosed clients will be invited to
participate in an in-depth interview about their experi-
ences of diagnosis, dialysis treatment and protective and
risk practices prior to and following diagnosis. Participants
from phase 2 will be interviewed at baseline (prior to
assessment), at assessment and 3–4 months after assess-
ment. Longitudinal data collection allows prospective
exploration of the barriers and facilitators to diagnostic
and treatment care, including wound resolution, dialysis
and injecting cessation support needs. A topic guide
orientates around these issues, with a focus on experiences
of the diagnostic and treatment pathway. This process also
allows observation of attrition. With consent, participants
will be accompanied by the lead researcher and the
Groundswell peer to the day-long diagnostic appointment.
Non-participant observations will be recorded through
field notes. Observations will explore the dynamics of
patient-provider and patient-peer communication pro-
cesses in situ, also enabling triangulation through observ-
ing events which are recounted in interviews.
Phase 4: SSTI protection and risk
We will concurrently employ a ‘positive deviance’ method-
ology to explore practices and contexts informing SSTI
protection and risk. A comparative sample of age and
injecting history matched PWID, with and without SSTI,
will be recruited from phase 2 survey sample (n = 30).
Snowball sampling will enable additional recruitment of
participants (n = 15–20) not in touch with drug services.
Participants will be interviewed once, with the option for
follow-up (up to 60 interviews among 45–50 participants).
Qualitative interviews will explore practices and know-
ledge of SSTI risk and care, the conditions which facilitate
or undermine SSTI care, barriers and facilitators to timely
treatment access, and experiences of health care systems.
It is important that this sample is distinct from, and not
dependent on, the phase 3 sample. This allows a focus
specifically on SSTI and protects against uncertainties of
the phase 3 sample size.
Sample size eligibility criteria and recruitment for phases
3 and 4
Phase 2 participants who consent to follow-up contact
will be stratified to enable purposive sampling for the
qualitative study phases (3 and 4). Phase 3 sample size is
dependent on proteinuria testing results; preliminary
calculations estimate ~ 12 participants. For phase 4, we
will purposively sample for variation in gender, age,
housing situation, injecting duration, drugs injected,
SSTI and hospitalisation history. Participants not in
touch with drug treatment services will be recruited
through snowball sampling. Women who inject drugs
are often disproportionately affected by SSTI, and face
additional barriers to service access, and therefore will
be actively recruited. The flexibility in phase 4 sample
size (n = ~ 50) allows both theoretical sampling and
saturation [50].
Phase 5: resource development
Phase 5 draws on the existing evidence base (phase 1)
and empirical data (phases 2–4) to inform the co-
construction of SSTI and AA amyloidosis intervention
resources and recommendations with stakeholders and
members of the affected community. A diagrammatic
logic model will describe anticipated resource delivery
mechanisms, components, mechanisms of impact and
intended outcomes. This will be informed by and act
as a guide to collaborative decision-making on re-
source content and design. Workshops with PWID and
providers at each site will be held at each phase of out-
put design. Budget is provided and collaboration devel-
oped (film-maker, designer) to enable production of
hard copy booklets and videos both for PWID and pro-
viders with dissemination enabled through social
media platforms, drug services, treatment provider and
drug user networks.
Mixed-methods analysis
Data generated for each phase will be analysed separately.
While single-phase analysis does not preclude each phase
building and drawing on previous analysis, it provides a
modest safeguard against dependence on previous phase
completion and validity [51]. Data triangulation, or mixed-
methods interpretation [51], will occur after phase 3 and 4
(qualitative study) completion; drawing inferences from
both quantitative and qualitative findings in relation to the
overarching research question, triangulation of mixed-
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methods data will prioritise complementarity (findings
greater than the sum of their parts), while also attentive to
convergence and dissonance [52].
Phase 2 analysis of quantitative survey and clinical
data will initially be descriptive, with the aim of generat-
ing overall prevalence estimates and according to partici-
pant characteristics (demographics, injecting history and
risk practices, SSTI history). Cross-sectional analyses will
be carried out using logistic regression and will examine
associations with two main outcomes: positive screen for
proteinuria and SSTI occurrence and severity. If the
prevalence of AA amyloidosis is high enough, this will
also be an outcome in our models. Predictors include
participant characteristics and risk behaviours. With the
outcome of +proteinuria, frequency of SSTI is the main
predictor to be tested.
Analysis of phase 3 and 4 qualitative data will follow
grounded theory principles [7], with verbatim transcripts
coded as collected in order to inform the direction of
subsequent interviews, coding, case selection, memo and
theory generation. Grounded theory is a systematic and
comparative method for studying processes [8], particu-
larly useful for generating substantive theory (grounded in
data) [8] with transferable potential for other sites and
conditions. Coding will be implemented in a step-wise
process; comprising open coding, focused coding, category
mapping and theme development. Through this process,
we will move from the particular to the general, the local-
ised to the abstract, with a focus on developing conceptual
density [53] and transferable mid-range theory.
Ethics and governance
Ethical approvals have been received from the NHS
Health Research Authority [17/LO/0872], the London
Bridge Research Ethics Committee [17/LO/0872] and
the LSHTM Observational Research Ethics Committee
[12021]. Informed written consent will be obtained from
each participant prior to enrolment and after informa-
tion and an explanation of the study purpose and proce-
dures is given. Participants will be asked to consent to
the following: (1) provide a urine sample to be tested for
protein and results shared with research team and
abnormal results being shared with their general practi-
tioner (GP); (2) to complete a confidential questionnaire
about their injecting practices and health history; (3) to
provide a confidential photo of their skin infection if
applicable; (4) to the anonymisation of data used in
study reports, papers and publications; (5) to the secure
storage of anonymised data in a data repository for use
by other researchers; (6) if referred to the NAC, the
results of any assessments to be shared with the research
team; (7) to be contacted for follow-up interview if
necessary and to be sent study outputs if desired; (8)
and if contacted for an in-depth-interview, for it to be
recorded and the transcript securely stored and anon-
ymised extracts be used in reports, papers or publica-
tions. The research is being carried out in accordance
with the principles, policies, procedures and guidelines
contained in the LSHTM Good Research Practice policy.
Results and discussion
The Care and Prevent study is innovative; it is the first
to assess screening feasibility and the prevalence of posi-
tive proteinuria (as a marker for AA amyloidosis) among
PWID accessing drug treatment services. This has po-
tentially significant implications. AA amyloidosis is an
under-recognised SSTI complication for which early
intervention is available but not employed [16, 47]. The
current evidence base for AA amyloidosis among PWID
spans back over four decades, yet epidemiological data
are weak; case reports predominate [47]. No UK data ex-
ists on the prevalence of AA amyloidosis among PWID,
and no international published research prospectively
explores early intervention for AA amyloidosis or bar-
riers to current care pathways. In the UK context where
AA amyloidosis risk is not screened for, most PWID are
referred to specialist assessment after renal failure is dis-
covered. Dialysis adherence is poor [16, 54], and deaths
from sepsis common [16]. Screening may enable early
intervention and avert renal failure. This has significant
cost savings and patient benefit potential.
Current status of the study and amendments
We commenced phase 2 data generation in September
2017. An unexpectedly high proportion (40/100) of partici-
pants recruited up to 22 November 2017 have had test
results indicating microalbuminuria (albumin: creatinine
ratio 3.4–33.9 mg/mmol). This necessitated a study amend-
ment for the development of a GP referral letter. Although
microalbuminuria is not an a priori outcome measure (we
are looking for macroalbuminuria > 30 mg/mmol), it indi-
cates raised risk for cardiovascular or progressive kidney
disease, and, therefore, with participants consent, we are
notifying their GP. In order to unpack the significance of
this finding, if microalbuminuria prevalence persists, we
have also added questions pertaining to smoking and inhal-
ation history (of tobacco and other drugs), family history of
kidney disease, and occurrence of scabies (associated with
microalbuminuria in indigenous populations [55]) and
blood in the urine. This was felt necessary given, general
population prevalence of microalbuminuria ranging
from 3.3% (women in the UK) [56] to 7.2% (the
Netherlands) [57] and, in the USA, 6% (men) and 9.7%
(women) [58]. While hepatitis C is associated with al-
buminuria and renal insufficiency, this does not appear
to account for preliminary findings—with prevalence of
microalbuminuria in people with hepatitis C reported
at 11–12% [59].
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Study implications
Our study has dual, inter-related aims. The findings will
determine whether AA amyloidosis risk screening is
warranted and envisage that screening recommenda-
tions, if required, will be for targeted implementation
rather than among all PWID at drug treatment services.
The linkage of individual questionnaire and screening
data facilitates the analysis of risk associations for
specific screening recommendations. Our study also pro-
vides insight into the nature and extent of the health
harms experienced by PWID in drug services, with a
specific focus on SSTI prevention and care. Regardless
of AA amyloidosis risk outcome, we know that timely
health care access for SSTIs is suboptimal among PWID
in the UK and places a huge burden not only on the
health care system but also on individual PWID in terms
of suffering, stigma and loss of mobility.
The value of our methodology is that we seek not only
to understand risk among those with SSTI, but also on
how protection is enabled. Participants include those with
lengthy injecting durations who have managed to ‘stay
safe’ while living on the street; their involvement and
insight is invaluable for the development of community-
acceptable interventions.
Our output content and format will be determined by
study findings and community acceptability. Resources
and recommendations are to be developed, drawing on
the evidence from phases 1 to 4, in collaboration with
PWID service user representatives and study partici-
pants. We envisage that intervention scope will encom-
pass not only SSTI and AA amyloidosis educational and
awareness resources, but also practical interventions to
enable self-care, such as wound care kits, and to support
injecting route transitions. Review evidence indicates
that favourable outcomes for AA amyloidosis among
PWID require not only effective SSTI treatment but also
injecting cessation [47]. It is unclear, however, whether it
is the act of injecting per se that exacerbates inflamma-
tion (and poor AA amyloidosis outcomes) or the inject-
ing risk environment which potentiates harm. Phase 3,
where we will follow those diagnosed with AA amyloid-
osis, may shed light on this question and provide insight
into the unique barriers faced by PWID in maintaining
the burden of dialysis care.
Strengths and limitations
Our study is, by necessity, exploratory. The prevalence
of AA amyloidosis is unknown among PWID in the UK;
formative data are required before implementation of
any larger scale screening study. As such, the sample size
for phase 2 is small (n = 400) but calculated as large
enough to provide sufficient power for our outcome
measures. Study sites are all situated in London, and the
sample population reflects those who engage with drug
treatment services, limiting generalisability of findings to
other locations or countries. PWID who do not seek
advice/treatment from drug treatment services may have
different experiences with SSTI than those who do
engage. Some recall bias is to be expected, as those who
experience, since those who experience more severe
SSTI may remember it differently from those who do
not. Some underreporting of stigmatised practices and
health conditions is also to be expected. Qualitative data,
however, may generate transferable insight, particularly
regarding barriers to SSTI care and interventions to fa-
cilitate protection and care among marginalised and
homeless populations.
Conclusions
We report the protocol for, and implementation status of,
the NIHR-funded study ‘Care and Prevent’. This study
innovates through implementing AA amyloidosis risk
screening among PWID in drug treatment services, follow-
ing those diagnosed through the care pathway and employ-
ing a positive deviance methodology to explore SSTI risk,
protection and care among PWID. Given the preponder-
ance of published literature and interventions targeting
blood-borne viruses among PWID, there is an urgent need
for innovative research and interventions for SSTI among
PWID—conditions which cause considerable suffering and
result in a high uptake of ambulatory care. AA amyloidosis
is a devastating yet preventable sequelae of SSTI among
PWID; we aim to ascertain if risk screening will benefit, or
unnecessarily burden, drug service clients.
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